A three-drug regimen consisting of bedaquiline, pretomanid, and linezolid (known as the BPaL regimen) had favorable outcomes in an uncontrolled clinical trial of 109 people with extensively drug-resistant TB (XDR-TB) as well as treatment-intolerant or nonresponsive multidrug-resistant TB.